Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Additionally, of the 37 peptides, 8 peptides (FETUB, A1AT, ITIH4, FA5, VWF, HGFA, BTD, VTNC) were also significant in the independent validation dataset (Supplementary Table S3-7).A plot of 37 significant peptides (from 27 proteins†) after linear mixed-effect model analysis. † CERU, Ceruloplasmin; FA12, Coagulation factor XII; A1AT, Alpha-1-antitrypsin; ANGT, Angiotensinogen; A2MG, Alpha-2-macroglobulin; APOA1, Apolipoprotein A-I; CRP, C-reactive protein; SAMP, Serum amyloid P-component; CO9, complement C9; VTDB, Vitamin D-binding protein; HEMO, Hemopexin; KLKB1, kallikrein B1; VTNC, Vitronectin; VWF, von Willebrand factor; PROS, Vitamin K-dependent protein S; CBG, Corticosteroid-binding globulin; FA5, Coagulation factor V; VINC, Vinculin; TAGL2, Transgelin-2; BTD, Biotinidase; RAP1B, Ras-related protein Rap-1b; 1433Z, 14-3-3 protein zeta/delta, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta; HGFA, Hepatocyte growth factor activator; SPP24, Secreted phosphoprotein 24; ITIH4, Inter-alpha-trypsin inhibitor heavy chain H4; FETUB, Fetuin B; TLN1, Talin-1; VPAR, Valproate responder (Alda A score of Valproate ≥ 5); VPANR, Valproate non-responder (Alda A score of Valproate < 5)

Source: Peptides that exhibited a distinct alteration in expression over time. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

) Considering the potential differences in treatment responses and prognoses among older individuals with BD, the age range of the participants was limited to 18 to 60 yrs.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study

Study design awaiting verification · International Journal of Bipolar Disorders · 2024

Original publication title

Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study

Hyunju Lee; Dohyun Han; Kyung Sue Hong; Kyooseob Ha; Hyeyoon Kim; Eun Young Cho; Woojae Myung; Sang Jin Rhee; Jayoun Kim; Tae Hyon Ha; Kang Eun Lee; Hye Won Jung; Yejin Lee; Dongbin Lee; Hyeona Yu; Daseul Lee; Yun Seong Park; Yong Min Ahn; Ji Hyun Baek; Se Hyun Kim

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The markers identified in this study could be valuable indicators of the underlying mechanisms associated with response to valproate treatment.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD. Patients with BD in remission were assessed only at baseline, whereas those experiencing acute mood episodes were evaluated at three points (baseline, 8 ± 2 weeks, and 6 ± 1 months).

The response to valproate treatment was measured using the Alda scale, with individuals scoring an Alda A score ≥ 5 categorized into the acute-valproate responder (acute-VPAR) group. We analyzed 158 peptides (92 proteins) from peripheral blood samples using multiple reaction monitoring mass spectrometry, and proteomic result-guided candidate gene association analyses, with 1,627 single nucleotide variants (SNVs), were performed using the Korean chip.

Source: Background

Abstract: Results

The markers of 37 peptides (27 protein) showed temporal upregulation, indicating possible association with response to valproate treatment. A total of 58 SNVs in 22 genes and 37 SNVs in 16 genes showed nominally significant associations with the Alda A continuous score and the acute-VPAR group, respectively. No SNVs reached the genome-wide significance threshold; however, three SNVs (rs115788299, rs11563197, and rs117669164) in the secreted phosphoprotein 2 gene reached a gene-based false discovery rate-corrected significance threshold with response to valproate treatment.

Significant markers were associated with the pathophysiological processes of bipolar disorders, including the immune response, acute phase reaction, and coagulation cascade. These results suggest that valproate effectively suppresses mechanisms associated with disease progression.

Source: Results

Abstract: Conclusions

The markers identified in this study could be valuable indicators of the underlying mechanisms associated with response to valproate treatment.

Source: Conclusions
Authors’ abstract

Background

Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD. Patients with BD in remission were assessed only at baseline, whereas those experiencing acute mood episodes were evaluated at three points (baseline, 8 ± 2 weeks, and 6 ± 1 months).

The response to valproate treatment was measured using the Alda scale, with individuals scoring an Alda A score ≥ 5 categorized into the acute-valproate responder (acute-VPAR) group. We analyzed 158 peptides (92 proteins) from peripheral blood samples using multiple reaction monitoring mass spectrometry, and proteomic result-guided candidate gene association analyses, with 1,627 single nucleotide variants (SNVs), were performed using the Korean chip.

Results

The markers of 37 peptides (27 protein) showed temporal upregulation, indicating possible association with response to valproate treatment. A total of 58 SNVs in 22 genes and 37 SNVs in 16 genes showed nominally significant associations with the Alda A continuous score and the acute-VPAR group, respectively. No SNVs reached the genome-wide significance threshold; however, three SNVs (rs115788299, rs11563197, and rs117669164) in the secreted phosphoprotein 2 gene reached a gene-based false discovery rate-corrected significance threshold with response to valproate treatment.

Significant markers were associated with the pathophysiological processes of bipolar disorders, including the immune response, acute phase reaction, and coagulation cascade. These results suggest that valproate effectively suppresses mechanisms associated with disease progression.

Conclusions

The markers identified in this study could be valuable indicators of the underlying mechanisms associated with response to valproate treatment.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40345-024-00342-x.

Publication and source details

Original title: Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study

Hyunju Lee; Dohyun Han; Kyung Sue Hong; Kyooseob Ha; Hyeyoon Kim; Eun Young Cho; Woojae Myung; Sang Jin Rhee; Jayoun Kim; Tae Hyon Ha; Kang Eun Lee; Hye Won Jung; Yejin Lee; Dongbin Lee; Hyeona Yu; Daseul Lee; Yun Seong Park; Yong Min Ahn; Ji Hyun Baek; Se Hyun Kim

International Journal of Bipolar Disorders · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100003725National Research Foundation of KoreaNRF-2019M3C7A1030625NRF-2019M3C7A1030624Ahn Yong Min Baek Ji Hyun

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T11:30:53.030290+00:00

DOI: 10.1186/s40345-024-00342-x · PMC11101393